Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Levinson, Nicholas M ^a   Boxer, Steven G ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; BOSUTINIB; IMATINIB; MUTANT PROTEIN; NITRILE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; VANDETANIB; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANILINE DERIVATIVE; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; DASATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FLUORESCENCE SPECTROSCOPY; HUMAN; INFRARED SPECTROSCOPY; ISOMER; PROTEIN DOMAIN; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; INFRARED SPECTROPHOTOMETRY; ISOMERISM; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; STATIC ELECTRICITY; X RAY DIFFRACTION;

ANILINE COMPOUNDS; BINDING SITES; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI; FUSION PROTEINS, BCR-ABL; HUMANS; ISOMERISM; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, MOLECULAR; MUTATION; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, INFRARED; STATIC ELECTRICITY; THIAZOLES; X-RAY DIFFRACTION;

EID: 84859478963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029828     Document Type: Article

References (51)

1. Sawyers CL, (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
7. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766.
8. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541.
9. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546.
10. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, et al. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117: 2562-2569.
11. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, et al. (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63: 375-381.
12. Cortes J, Kantarjian HM, Baccarani M, Brummendord TH, Liu D, et al. (2006) A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib. Blood 108: 168.
13. Cortes JE, Kantarjian H, Brümmendorf T, Khoury HJ, Kim D, et al. (2010) Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). J Clin Oncol 28: 487.
14. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, et al. (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66: 11314-11322.
15. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, et al. (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7: 1185-1194.
16. Campone M, Bondarenko I, Brincat S, Epstein RJ, Munster PN, et al. (2007) Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Breast Cancer Res Treat pp. 106.
17. Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, et al. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 14: 3135-3139.
18. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, et al. (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15: 299-311.
19. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, et al. (2009) Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res 69: 2384-2392.
20. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, et al. (2006) Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A 103: 3563-3568.
21. Leslie AGW, (1992) Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4+ESF-EAMCB Newsletter on Protein Crystallography 26.
22. CCP4 (1994) The CCP4 Suite: programs for protein crystallography. Acta Cryst, D 50: 760-763.
23. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
24. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, et al. (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66: 1007-1014.
25. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
26. Dauter Z, Dauter M, de La Fortelle E, Bricogne G, Sheldrick GM, (1999) Can anomalous signal of sulfur become a tool for solving protein crystal structures? Journal of Molecular Biology 289: 83-92.
27. Andrews SS, Boxer SG, (2000) Vibrational Stark Effects of Nitriles I. Methods and Experimental Results. J Phys Chem A 104: 11853-11863.
28. Andrews SS, Boxer SG, (2000) A liquid nitrogen immersion cryostat for optical measurements. Review of Scientific Instruments 71: 3567-3569.
29. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, et al. (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44: 3965-3977.
30. Yin XJ, Xu GH, Sun X, Peng Y, Ji X, et al. (2010) Synthesis of Bosutinib from 3-Methoxy-4-hydroxybenzoic Acid. Molecules 15: 4261-4266.
31. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
32. Stamos J, Sliwkowski MX, Eigenbrot C, (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272.
33. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66: 5790-5797.
34. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, et al. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27: 469-471.
35. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
36. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, et al. (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767-772.
37. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
38. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075.
39. Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, et al. (2001) Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 44: 822-833.
40. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, et al. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942.
41. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, et al. (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 99: 10700-10705.
42. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236-4243.
43. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, et al. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 4: e144.
44. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-871.
45. Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, et al. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A 106: 139-144.
46. Yamaguchi H, Hendrickson WA, (1996) Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384: 484-489.
47. Hubbard SR, (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581.
48. Toledo LM, Lydon NB, Elbaum D, (1999) The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 6: 775-805.
49. Suydam IT, Boxer SG, (2003) Vibrational Stark effects calibrate the sensitivity of vibrational probes for electric fields in proteins. Biochemistry 42: 12050-12055.
50. Suydam IT, Snow CD, Pande VS, Boxer SG, (2006) Electric fields at the active site of an enzyme: direct comparison of experiment with theory. Science 313: 200-204.
51. Webb LJ, Boxer SG, (2008) Electrostatic fields near the active site of human aldose reductase: 1. New inhibitors and vibrational stark effect measurements. Biochemistry 47: 1588-1598.